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Abstract
Our goal is to test the effect of both rare and common variants in a blood pressure study. We use a pathway-
based approach, gene-set enrichment analysis, to search for related genes affecting 4 phenotypes: systolic blood
pressure, diastolic blood pressure, the difference between each of them and mean arterial pressure, which is a
weighted linear combination of systolic and diastolic blood pressure. Using the real Genetic Analysis Workshop
18 data, we consider both rare and common variants in our analysis and incorporate other covariates by using a
recently proposed test statistic.
Our study identified a commonly enriched gene set/pathway for the two derived phenotypes we analyzed: the
difference between systolic and diastolic blood pressure and mean arterial pressure, but none is identified with the
individual blood pressure phenotypes. The gene CD47, in the enriched gene pathway/set, was reported in previous
studies to be related to blood pressure.
The findings are not surprising because the sample size we use in our analysis is small, and hence power to detect
small but important effects is likely inadequate.
Background
Worldwide, hypertension contributes to more than 10 mil-
lion deaths and it affects one-third of the adult population
per year [1]. It was predicted that the incidence of hyper-
tension among adults in 2025 will reach 1.56 billion and
contribute to approximately 54% of stroke and 47% of
ischemic heart disease. Furthermore, it is a major risk fac-
tor for cardiovascular disease [2]. Several factors, including
genetic, environmental, and demographic factors, play a
major role in the development of hypertension. However,
it is believed that 30% to 60% of the variability in blood
pressure (BP) is inherited [1].
Many genome-wide association studies (GWAS) have
been conducted to identify single-nucleotide polymorph-
ism (SNPs) that are significantly associated with systolic
blood pressure (SBP), diastolic blood pressure (DBP),
and/or hypertension.
Meta-analysis findings of the Global BPgen (Global
Blood Pressure Genetics) consortium (n = 34,433) and
CHARGE (The Cohorts for Heart and Aging Research
in Genome Epidemiology) consortium (n = 29,136)
based on populations of European ancestry identified
4 loci significantly associated with SBP (ATP2B1,
CYP17A1, PLEKHA7, SH2B3), 6 associated with DBP
(ATP2B1, CACNB2, CSK-ULK3, SH2B3, TBX3-TBX5,
ULK4), and 1 associated with hypertension (ATP2B1)
[1]. However, a genome-wide association study by
Adeyemo et al [3] based on a population of African
Americans (n = 1017) identified significant loci for SBP
in or near the genes PMS1, SLC24A4, YWHA7, IPO7,
and CACANA1H, while no significant loci were discov-
ered to be associated with DBP or hypertension.
Unlike single-gene analysis, pathway-based approaches
consider multiple genes that are related together within
gene sets/pathways; these pathways are predefined gene sets
from biological databases. The aim of pathway-based
approaches is to assess the significance of these sets/path-
ways by evaluating the enrichment of genes within a path-
way at the top of a list of ranked genes [4-6]. Pathway-based
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analysis was originally applied to gene expression data; how-
ever, it has also been applied to GWAS data [4]. In this
paper, we use a pathway-based approach based on Gene Set
Enrichment Analysis (GSEA) [4]. We consider both rare
and common variants and incorporate other covariates,
including age, gender, use of antihypertensive medications,
and smoking status. Our main focus is to test the effects of
both rare and common variants on SBP, DBP, the difference
between them (SBP-DBP), and mean arterial pressure
(defined as MAP = [⅔ DBP] + [⅓ SBP]) by applying GSEA.
Methods
Phenotype and covariate data description
This data set was provided by the organizers of the
Genetic Analysis Workshop 18 (GAW18). From this data
set, we considered the 157 unrelated individuals with their
phenotypes. Phenotypes were taken at 4 time points and
included systolic and DBP measurements and hyperten-
sion. The following covariates were also provided: age,
smoking status, antihypertensive medications usage, and
gender. In our analysis, we used the baseline data; among
the 157 unrelated individuals we had 129 individuals who
had been genotyped. Table 1 summarizes the data.
Genotype data description
Genotype data were provided only for odd-numbered
autosomal chromosomes. In this paper, we focus on var-
iants on chromosome 3 (as suggested by the GAW18
organizers to allow comparisons of findings with other
GAW18 contributions).
Pathway-based analysis
We considered 4 phenotypes of interest SBP, DBP, SBP-
DBP, and MAP and performed pathway-based analysis.
We followed the following steps [4,5]:
Step 1: Mapping SNPs to genes
Among the 1,215,296 SNPs on chromosome three,
523,147 SNPs were mapped to 1224 known genes using
NBCI2R.
Step 2: Obtaining test statistics for genes
We considered both rare and common variants and
other covariates (age, smoking status, medications use,
and gender) to assign a test statistic for each gene. VW-
TOW (variable weight test for testing the effect of an
optimally weighted combination of variants) [8] was
used to construct test statistics and their p values.
Assume that we have n individuals who have been geno-
typed at M variants and is the trait of interest for the ith
individual. Each individual has a genotypic score T
where {0,1,2} denotes the number of copies of the
minor allele for the mth variant of the ith individual. We
used a minor allele frequency (MAF) threshold of less
than 1% to define rare variants. To test the effect of the
















are the optimal weights.
To test the effect of both rare and common variants,
we applied TOW to each of them separately; Tr and Tc
denote these statistics, respectively. Then we used the
test statistic of VW-TOW:
TVW T = min
0≤λ≤1
pλ




+ (1 − λ) Tc√
var(Tc)
. To evaluate the p
value of TVW T, we used the permutation test.
We incorporated the other covariates (zi1, . . . , zip)T for
each individual i , by adjusting yi and xim using linear
regression:
yi = α0 + α1zi1 + . . . + αpzip + i and
xim = α0m + α1mzi1 + . . . + αpmzip + τim
And by using the residuals y˜i and x˜im, the following
TOW and VW-TOW were used:
TTOW = TT|yi=y˜i,xim=x˜im and
TVW TOW = TVW−T|yi=y˜i,xim=x˜im
Step 3: Pathway analysis
We ranked all the genes (N), that had p values and test
statistics, based on their statistical significance from the
smallest to the largest p values. From step 2, we had (N =
1187) genes for SBP and DBP and (N = 1188) genes for
SBP-DBP and MAP. Using the GSEA method [6], we eval-
uated the significance of predefined gene sets/pathways
obtained from online pathway databases (The Molecular
Table 1 Descriptive statistics for phenotypes and
covariates at baseline for 129 unrelated individuals
Variable Summary measure*
SBP 128.4 ± 21.8
DBP 71.8 ± 9.2
MAP 90.7 ± 11.6
SBP-DBP 56.6 ± 19
Hypertension (Yes, No) 129 (29.5)
Age 52.9 ± 15.6
Sex (Female) 129 (60.5)
Medications use (Yes, No) 129 (20.2)
Smoking status (Yes, No) 129 (24.8)
*Mean ± SD for continuous variables; n(%) for categorical variables.
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Signatures Database) [9]. We used the c2 curated gene sets
(v3.1), which are compiled from online pathway databases,
publications in PubMed, and knowledge of domain experts
[9], which consisted of 4850 gene sets, but we only consid-
ered 3638 sets that had at least 1 gene from chromosome
3 and at least 10 genes in total. Of the 3638 pathways,
69.1% have between 1 and 5 genes on chromosome 3,
while 24.1% of the pathways have between 6 and 20 genes
and 6.8% have between 21 and 140 genes on the same
chromosome. Then we calculated the enrichment score
(ES) for each set/pathway using a weighted Kolmogorov-
Smirnov-like running-sum statistic. This statistic describes
the overrepresentation of the genes within the set at the
top of the ranked genes. We then adjusted for different
sizes of genes using 1000 gene-based permutations (π) and





To estimate the significance level of NES for each set/
pathway, we used the gene-based permutation approach
to obtain the empirical p values of the NES. We used
1000 gene-set permutations and then we considered the
set/pathway to be significantly enriched if its false dis-
covery rate (FDR) q value is less than 0.05. We imple-
mented the analysis using the GSEApreranked tool
included in the GSEA software [6,7].
Results
Considering common and rare variants from chromo-
some 3 with other covariates, and applying GSEA to our
data, we ranked the top 10 gene sets/pathways based on
their FDR q values for each phenotype. These ranked
genes are listed in Tables 2, 3, 4, and 5 for MAP, (SBP-
DBP), SBP, and DBP phenotypes, respectively. We
found that no gene sets were enriched when we consid-
ered SBP or DBP. However, we were able to identify 1
significant enriched gene pathway from c2 curated gene
sets (Table 2) with MAP. Interestingly, the same path-
way was declared to be significantly enriched with the
difference between SBP and DBP phenotype (Table 3).
We identified the same gene pathway (Koyama_Se-
ma3B_Targets_DN) in both phenotypes, and this
Table 2 The top 10 gene sets/pathways from c2 curated gene sets ranked by FDR q values for MAP
Pathway name No. genes* ES NES FDR q value
KOYAMA_SEMA3B_TARGETS_DN 18 0.611 2.226 0.040
HUANG_GATA2_TARGETS_UP 11 0.559 1.769 0.903
ONO_FOXP3_TARGETS_DN 5 0.724 1.757 0.929
BENPORATH_ES_2 4 0.859 1.938 0.967
CARDOSO_RESPONSE_TO_GAMMA_RADIATION_AND_3AB 3 0.865 1.770 0.980
ZHANG_TLX_TARGETS_60HR_UP 22 0.423 1.625 0.981
LAIHO_COLORECTAL_CANCER_SERRATED_DN 1 0.891 1.202 0.992
PID_INTEGRIN2_PATHWAY 1 0.915 1.203 0.992
LIU_TARGETS_OF_VMYB_VS_CMYB_DN 5 0.501 1.203 0.992
LIM_MAMMARY_STEM_CELL_DN 21 0.317 1.203 0.992
*Number of genes on chromosome 3.
Table 3 The top 10 gene sets/pathways from c2 curated gene sets ranked by FDR q-values for the difference between
SBP and DBP
Pathway name No. genes* ES NES FDR q value
KOYAMA_SEMA3B_TARGETS_DN 18 0.614 2.227 0.042
ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_UP 4 0.830 1.867 0.822
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP 7 0.691 1.888 0.823
BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_DN 4 0.811 1.844 0.871
LI_INDUCED_T_TO_NATURAL_KILLER_DN 7 0.693 1.907 0.892
BENPORATH_ES_2 4 0.858 1.941 0.917
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_GRANULOCYTE_UP 3 0.869 1.762 0.958
CHANG_CORE_SERUM_RESPONSE_DN 21 0.290 1.091 0.976
WONG_ENDMETRIUM_CANCER_UP 2 0.625 1.082 0.976
NOUZOVA_TRETINOIN_AND_H4_ACETYLATION 18 0.299 1.090 0.976
*Number of genes on chromosome 3.
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pathway had been shown to be related to different kinds
of cancer [10,11]. In this pathway, 12 of 18 genes on
chromosome 3 contributed to the enrichment score and
the most interesting gene in this pathway is CD47. Sev-
eral articles [12,13] reported that this gene regulates BP.
Because our pathway-based analysis is restricted to
genes on chromosome 3, the number of pathways used
for analysis exceeded the number of genes, which can
have important implications in interpreting our findings.
The results from our analyses should be interpreted
cautiously.
Conclusions
Gene-set enrichment analysis considers multiple genes
that are related biologically. In our data, we identified 1
identical enriched gene set/pathway with the MAP and
the difference between SBP and DBP. The gene CD47 in
this pathway was reported previously to be related to BP.
Our analysis included only 129 unrelated individuals.
Sample size plays a major role in identifying enriched
gene sets/pathways, which could explain the lack of sig-
nificant pathways in our analysis. Future studies can be
done by applying GSEA on large family-based data
where incorporating both rare and common variants,
taking into account the correlations between individuals
and increasing the sample size, may lead to new
discoveries.
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